Project Grant R21CA293424
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$181K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to conduct research targeting glioblastoma stem cells. The research aims to leverage insights from aging in the nervous system and the molecular circuitry of cancer stem cells to understand how aging promotes tumor growth through cell autonomous mechanisms and interactions with the microenvironment. The project will leverage spatial transcriptomics and...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is for a project titled "Engineered Biomimetic Collective Cancer Invasion Models for Screening Chemotherapeutic Agents." The $443,191 award, with a project period running from June 2024 to May 2029, aims to develop innovative in vitro tumor invasion models using engineered biomimetic substrates and 3D tissue-engineered constructs. These models will...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 "Cancer Biology Research" provides $700,690 to Health Research, Inc. at Roswell Park to decipher the molecular mechanisms driving breast cancer bone metastasis. The award aims to understand how the transcriptional coactivators YAP/TAZ regulate metabolic processes in microscopic bone metastases and how this drives the progression to established bone metastases. The researchers will investigate the crosstalk...
The National Cancer Institute (NCI) awarded a $222,027 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to develop a novel computational imaging algorithm that can characterize the mechanobiological properties of the tumor microenvironment. The key objectives are to: Develop a computational imaging algorithm that can quantitatively capture the intrinsic mechanobiological properties of the cellular and acellular components within 3D tumor microenvironments,...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $585,931 to the University of Pittsburgh to conduct research aimed at evaluating and selecting the most representative cancer models, such as cell lines and patient-derived organoids, for use in precision cancer research and clinical applications. The key objectives are to: 1) identify and clinically annotate prevalent tumor subclones and microenvironment cell types in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584 to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The key objectives are to: 1) Study the genomic and phenotypic evolution of metastatic precursor cells during dissemination, 2) Investigate gene expression...
This federal Project Grant award of $389,988, awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), supports research to investigate the role of tRNA modifications in glioblastoma (GBM) stem cell maintenance and tumor growth. The primary awardee, the University of Pittsburgh, will use mass spectrometry and ribosome profiling techniques to study how altered tRNA modifications influence the translational landscape in GBM stem cells. The goal is to provide molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University provides $622,329 to conduct research aimed at modulating the growth, progression, and metastasis of triple-negative breast cancer (TNBC) by inhibiting the MDA-9 protein. The key objectives are to: 1) formulate a small molecule inhibitor of MDA-9 called PDZ1I-Nano for clinical use and characterize its non-cell-autonomous anti-tumor effects, particularly on...
This $1,242,611.36 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by The Medical College of Wisconsin, Inc. to investigate the role of the chemokine CCL24 in driving the metastatic progression of aggressive breast cancer. The key products and services to be delivered under this award include: 1) Determining the clinical significance of CCL24 expression in breast cancer and its association with...
The National Cancer Institute (NCI) awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a hybrid type I cluster randomized effectiveness-implementation trial of the CARES intervention, an integrated EHR-based screening and stepped collaborative care program designed to improve health-related quality of life for cancer patients experiencing depression, pain, and fatigue. The overarching...